Safety Comparison: Expert Clinical Analysis & UK Pricing
Which Is Safer Mounjaro or Wegovy: Clinical Safety Profiles
When evaluating which is safer Mounjaro or Wegovy, both prescription-only medicines have undergone extensive clinical trials with similar safety profiles. Wegovy (semaglutide) demonstrated consistent safety across the STEP trial programme, with the most common side effects being gastrointestinal, including nausea, vomiting, and diarrhoea, typically occurring during dose escalation phases. Mounjaro (tirzepatide) showed comparable safety in the SURMOUNT trials, with similar gastrointestinal side effects but potentially different frequencies due to its dual-receptor mechanism.
The key difference lies in their mechanisms: Wegovy targets GLP-1 receptors exclusively, whilst Mounjaro acts on both GIP and GLP-1 receptors as a dual agonist. This dual action may influence tolerability patterns, though both treatments require careful dose escalation and clinical monitoring. At EverydayMeds, our clinical team assesses individual patient factors to help determine which treatment may be more suitable, considering medical history, current medications, and individual risk factors.
UK Pricing Comparison: Wegovy and Mounjaro Value Analysis
For patients considering which is safer Mounjaro or Wegovy, cost considerations often influence treatment decisions alongside safety profiles. Wegovy pricing at EverydayMeds starts from £79.99 for the 0.25mg starter dose (using code FIRST40 for new customers or DOSE25 for returning patients), progressing through £94.99 (0.5mg), £99.99 (1mg), £139.99 (1.7mg), to £209.99 for the 2.4mg maintenance dose. Our Getting Started bundles, such as the Intro Duo (0.25mg & 0.5mg) for £169.99, provide convenient multi-dose packages for the initial escalation period.
Mounjaro pricing follows a different structure due to its distinct dosing schedule and mechanism. Both treatments include comprehensive clinical assessment, prescriber review, and next-day cold-chain delivery as standard. The complete pricing transparency allows patients to budget effectively whilst receiving expert clinical guidance on which treatment may offer the best safety and efficacy profile for their individual circumstances.
Clinical Trial Evidence: Mounjaro vs Wegovy Safety Data
Clinical evidence helps inform which is safer Mounjaro or Wegovy for individual patients. In the STEP trials, Wegovy demonstrated that patients experienced predominantly gastrointestinal side effects, with serious adverse events occurring at low rates and comparable to other GLP-1 treatments. The SELECT cardiovascular outcomes trial showed a 20% reduction in major cardiovascular events, providing additional safety reassurance for eligible patients.
Mounjaro's SURMOUNT trials revealed similar gastrointestinal tolerability patterns, though the dual-receptor mechanism may influence the specific side effect profile. Both treatments require monitoring for potential thyroid concerns and have similar contraindications, including personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2.
Mechanism Differences: How Safety Profiles Compare
Understanding mechanism differences helps clarify which is safer Mounjaro or Wegovy for specific patients. Wegovy works as a GLP-1 receptor agonist, mimicking the natural incretin hormone GLP-1 to reduce appetite, slow gastric emptying, and promote satiety after smaller meals. This targeted approach has been extensively studied across multiple patient populations, with well-characterised side effects primarily related to the gastrointestinal system. The mechanism also influences brain appetite centres, potentially reducing food cravings whilst supporting sustainable eating pattern changes. Clinical experience with GLP-1 agonists spans over a decade, providing substantial real-world safety data beyond clinical trial settings.
EverydayMeds Assessment Process: Ensuring Treatment Safety
Our clinical assessment process helps determine which is safer Mounjaro or Wegovy based on individual patient factors. The 3-minute online assessment covers medical history, current medications, previous weight management attempts, and specific risk factors that might influence treatment choice. Our prescribers, working under GPhC registration #9012878, review each application within 3 working days (or 24 hours with express service), considering contraindications, drug interactions, and patient preferences. Once approved, next-day delivery ensures treatment begins promptly with comprehensive patient information and ongoing support. Our clinical team remains available for questions throughout treatment, helping monitor for side effects and adjusting approaches as needed.
Storage and Practical Considerations: Wegovy vs Mounjaro
Practical factors may influence which is safer Mounjaro or Wegovy in real-world use. Wegovy offers superior storage flexibility, remaining stable at room temperature for up to 6 weeks once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. Both use pre-filled injection pens, though Wegovy's FlexTouch pen system has extensive patient familiarity from other Novo Nordisk treatments. The dose escalation schedule differs between treatments, with Wegovy following a 16-week escalation to maintenance dosing, whilst Mounjaro uses a different timeline. Storage convenience may be particularly relevant for patients who travel frequently or have limited refrigeration access.
Individual Risk Assessment: Personalised Safety Evaluation
Determining which is safer Mounjaro or Wegovy requires individualised risk-benefit analysis considering patient-specific factors. Patients with established cardiovascular disease may benefit from Wegovy's proven cardiovascular outcomes data from the SELECT trial. Those with specific gastrointestinal sensitivities might respond differently to each treatment's side effect profile, though both require similar monitoring approaches.
Age, concurrent medications, and weight management goals all influence treatment selection. Our clinical assessment captures these nuances, ensuring patients receive treatments aligned with their safety profile and clinical needs. Both Mounjaro and Wegovy are available from EverydayMeds, with prescriber guidance helping determine the most appropriate option for individual circumstances.
Complete Treatment Value: Safety Monitoring and Support
At EverydayMeds, we ensure patients considering which is safer Mounjaro or Wegovy receive comprehensive support beyond competitive pricing. Our service includes detailed safety information, injection technique guidance, side effect management advice, and ongoing clinical support throughout treatment. New customers use code FIRST40 at checkout, whilst returning customers apply DOSE25 to access our transparent pricing structure. Both treatments must be used alongside a reduced-calorie diet and increased physical activity for optimal results and safety.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
